‘Rare’ case included ‘campaigning element’ says judge | Ex-student sought clarification on royalties from university | 651-paragraph ruling required Oxford Uni to justify its IP policies.
Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.
Medicines Patent Pool deals have given 20 million people access to HIV treatment | Full list of sub-licensees.
Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Firms aim to form a UPC litigation alliance | New court has significant implications for life sciences | UPC faces calls for delay over concerns regarding its case management system.
The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.
European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.
The lawsuit centres on patented molecular instruments | The patents-in-suit cover cover features of RNAscope tech.
Evidence shows medicines approved as biosimilars in the EU may be prescribed interchangeably | Additional ‘switch’ studies no longer not need to be carried out.
Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition